04.11.17
Accenture will work with BioCelerate, a subsidiary of TransCelerate BioPharma Inc., a nonprofit focused on improving efficiencies in R&D, to develop a platform enabling its member companies to aggregate and analyze preclinical and clinical information to improve drug development efficiency.
“The ability to collect and leverage large amounts of precompetitive information to create new insights in the R&D process is an important development in the preclinical research space, said Kevin Julian, senior managing director, Accenture Life Sciences North America and Accelerated R&D Services. “We are eager to collaborate with BioCelerate on this critical initiative to further enable the sharing of data to maximize the value of preclinical and clinical research and deliver better patient outcomes.”
The R&D data sharing platform will be built on the Accenture Insights Platform, a portfolio of advanced analytics capabilities, and an integrated design, build, run environment, to enable the development of function-specific analytics solutions.
The platform will provide participating member companies the ability to assimilate, aggregate, and analyze de-identified preclinical and clinical information, enabling them to draw conclusions from a large data set. The platform will be used initially to support BioCelerate’s first collaborative project, Toxicology & Background Control Data Sharing, to enhance product safety.
“Sharing preclinical data among the BioCelerate member companies can be a powerful tool for improving drug discovery and development. With this initiative, BioCelerate members will be able to make more informed decisions on compound progression based on a better understanding of preclinical safety data,” said Mike Graziano Ph.D., DABT, vice president of Drug Safety Evaluation at BMS and lead for the BioCelerate initiative.
Following launch of the platform, data from TransCelerate’s Placebo Standard of Care Data Sharing (PSoC) initiative will be migrated, creating the foundation for additional preclinical and clinical data sharing across member companies.
“The ability to collect and leverage large amounts of precompetitive information to create new insights in the R&D process is an important development in the preclinical research space, said Kevin Julian, senior managing director, Accenture Life Sciences North America and Accelerated R&D Services. “We are eager to collaborate with BioCelerate on this critical initiative to further enable the sharing of data to maximize the value of preclinical and clinical research and deliver better patient outcomes.”
The R&D data sharing platform will be built on the Accenture Insights Platform, a portfolio of advanced analytics capabilities, and an integrated design, build, run environment, to enable the development of function-specific analytics solutions.
The platform will provide participating member companies the ability to assimilate, aggregate, and analyze de-identified preclinical and clinical information, enabling them to draw conclusions from a large data set. The platform will be used initially to support BioCelerate’s first collaborative project, Toxicology & Background Control Data Sharing, to enhance product safety.
“Sharing preclinical data among the BioCelerate member companies can be a powerful tool for improving drug discovery and development. With this initiative, BioCelerate members will be able to make more informed decisions on compound progression based on a better understanding of preclinical safety data,” said Mike Graziano Ph.D., DABT, vice president of Drug Safety Evaluation at BMS and lead for the BioCelerate initiative.
Following launch of the platform, data from TransCelerate’s Placebo Standard of Care Data Sharing (PSoC) initiative will be migrated, creating the foundation for additional preclinical and clinical data sharing across member companies.